KZA — Kazia Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- AU$18.24m
- AU$14.80m
- AU$0.02m
Annual income statement for Kazia Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | R2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.1 | 0.066 | 15.2 | 0.002 | 0.023 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.88 | 12.7 | 24.1 | 25.4 | 20.8 |
| Operating Profit | -8.78 | -12.6 | -8.91 | -25.4 | -20.7 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.6 | -12.8 | -8.91 | -25.4 | -20.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.3 | -12.5 | -8.42 | -25 | -20.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.3 | -12.5 | -8.42 | -25 | -20.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.3 | -12.5 | -8.42 | -25 | -20.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.17 | -0.16 | -0.057 | -0.189 | -0.123 |